Eisai Co., Ltd. (ESAIY)
ESAIY Stock Price Chart
Explore Eisai Co., Ltd. interactive price chart. Choose custom timeframes to analyze ESAIY price movements and trends.
ESAIY Company Profile
Discover essential business fundamentals and corporate details for Eisai Co., Ltd. (ESAIY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2 Feb 2023
Employees
11.07K
Website
https://www.eisai.co.jpCEO
Haruo Naito
Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
ESAIY Financial Timeline
Browse a chronological timeline of Eisai Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 5 Feb 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 31 Jul 2025
Earnings released on 15 May 2025
Earnings released on 7 Feb 2025
Earnings released on 8 Nov 2024
Dividend declared on 30 Sept 2024
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 4 Dec 2024.
Earnings released on 2 Aug 2024
EPS came in at $36.95 , while revenue for the quarter reached $189.03B .
Earnings released on 15 May 2024
EPS came in at $46.37 , while revenue for the quarter reached $190.50B .
Dividend declared on 27 Mar 2024
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 12 Jun 2024.
Earnings released on 7 Mar 2024
EPS came in at $20.81 , while revenue for the quarter reached $177.70B .
Earnings released on 6 Feb 2024
EPS came in at $9.72 , while revenue for the quarter reached $176.62B .
Dividend declared on 28 Sept 2023
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 4 Dec 2023.
Earnings released on 30 Jun 2023
EPS came in at $70.92 , while revenue for the quarter reached $196.94B .
Earnings released on 31 Mar 2023
EPS came in at $56.89 , while revenue for the quarter reached $198.21B .
Dividend declared on 30 Mar 2023
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 12 Jun 2023.
Earnings released on 31 Dec 2022
EPS came in at $30.14 , while revenue for the quarter reached $187.57B .
Earnings released on 30 Sept 2022
EPS came in at $12.44 , while revenue for the quarter reached $174.36B .
Earnings released on 30 Jun 2022
EPS came in at $93.79 , while revenue for the quarter reached $184.26B .
Earnings released on 31 Mar 2022
EPS came in at -$43.26 , while revenue for the quarter reached $190.90B .
Earnings released on 31 Dec 2021
EPS came in at $49.44 , while revenue for the quarter reached $202.97B .
Earnings released on 30 Sept 2021
EPS came in at $14.03 , while revenue for the quarter reached $163.46B .
Earnings released on 30 Jun 2021
EPS came in at $147.07 , while revenue for the quarter reached $198.89B .
Earnings released on 31 Mar 2021
EPS came in at -$10.64 , while revenue for the quarter reached $147.61B .
Earnings released on 31 Dec 2020
EPS came in at $67.54 , while revenue for the quarter reached $181.29B .
Earnings released on 30 Sept 2020
EPS came in at $4.78 , while revenue for the quarter reached $151.46B .
ESAIY Stock Performance
Access detailed ESAIY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.